Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer
Honglin Tang, Yanzhuo Liu, Chenlong Wang, et al.
Journal of Pharmacology and Experimental Therapeutics (2018) Vol. 368, Iss. 3, pp. 401-413
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Pericytes in the tumor microenvironment
Zhongyi Jiang, Jing Zhou, Luohong Li, et al.
Cancer Letters (2023) Vol. 556, pp. 216074-216074
Open Access | Times Cited: 65
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
Emily Hays, Benjamin Bonavida
Drug Resistance Updates (2019) Vol. 43, pp. 10-28
Closed Access | Times Cited: 116
Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles
Alena Líšková, Marek Samec, Lenka Koklesová, et al.
The EPMA Journal (2021) Vol. 12, Iss. 2, pp. 155-176
Open Access | Times Cited: 98
Opportunities for Small Molecules in Cancer Immunotherapy
Sabina Y. van der Zanden, Jolien J. Luimstra, Jacques Neefjes, et al.
Trends in Immunology (2020) Vol. 41, Iss. 6, pp. 493-511
Closed Access | Times Cited: 95
Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model
Jing Wu, Xiaogang Zhao, Qifeng Sun, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 125, pp. 109746-109746
Open Access | Times Cited: 80
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
Robby Barnestein, Loïck Galland, Laura Kalfeist, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 54
Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer
Lilong Liu, Min Mo, Xuehan Chen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 32
Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions
Rendy Hosea, Sharon Hillary, Shourong Wu, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3506-3506
Open Access | Times Cited: 28
Enhancement of tumour penetration by nanomedicines through strategies based on transport processes and barriers
Yang Huang, Zongrui Tong, Shichao Sun, et al.
Journal of Controlled Release (2020) Vol. 328, pp. 28-44
Closed Access | Times Cited: 50
The molecular mechanism of METTL3 promoting the malignant progression of lung cancer
Chao Ma, Ruijie Ma, Kang Hu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 27
USP51/PD‐L1/ITGB1‐deployed juxtacrine interaction plays a cell‐intrinsic role in promoting chemoresistant phenotypes in non‐small cell lung cancer
Jianjun Li, Xuechun Xiao, Yang Ou, et al.
Cancer Communications (2023) Vol. 43, Iss. 7, pp. 765-787
Open Access | Times Cited: 16
Flavonoids in the Treatment of Non-small Cell Lung Cancer via Immunomodulation: Progress to Date
Mengdi Liang, Yang Huang, Shengfeng Huang, et al.
Molecular Diagnosis & Therapy (2025)
Closed Access
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
Federico Nichetti, Francesca Ligorio, Emma Zattarin, et al.
Cancers (2019) Vol. 12, Iss. 1, pp. 67-67
Open Access | Times Cited: 51
Immune metabolism in PD-1 blockade-based cancer immunotherapy
Alok Kumar, Kenji Chamoto
International Immunology (2020) Vol. 33, Iss. 1, pp. 17-26
Open Access | Times Cited: 36
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Yaqi Li, Jing Liu, Long Gao, et al.
Immunology Letters (2019) Vol. 220, pp. 88-96
Closed Access | Times Cited: 26
The PD-L1 metabolic interactome intersects with choline metabolism and inflammation
Jesús Pacheco‐Torres, Marie‐France Penet, Yelena Mironchik, et al.
Cancer & Metabolism (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
Naoya Maekawa, Satoru Konnai, Yumie Asano, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Icariside II potentiates the anti-PD-1 antitumor effect by reducing chemotactic infiltration of myeloid-derived suppressor cells into the tumor microenvironment via ROS-mediated inactivation of the SRC/ERK/STAT3 signaling pathways
Qing Kong, Mengyu Ma, Li Zhang, et al.
Phytomedicine (2022) Vol. 110, pp. 154638-154638
Closed Access | Times Cited: 14
Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review
Sajad Fakhri, Seyed Zachariah Moradi, Farahnaz Faraji, et al.
Cancer and Metastasis Reviews (2023) Vol. 43, Iss. 1, pp. 501-574
Closed Access | Times Cited: 8
circ-Keratin 6c Promotes Malignant Progression and Immune Evasion of Colorectal Cancer through microRNA-485-3p/Programmed Cell Death Receptor Ligand 1 Axis
Zhipeng Jiang, Zehui Hou, Wei Liu, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 377, Iss. 3, pp. 358-367
Open Access | Times Cited: 19
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
Chuanhui Han, Anli Zhang, Zhida Liu, et al.
Oncogene (2020) Vol. 40, Iss. 5, pp. 885-898
Closed Access | Times Cited: 17
The Trinity of Matrix Metalloproteinases, Inflammation, and Cancer: A Literature Review of Recent Updates
Erva Özkan, Filiz Bakar‐Ates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (2019) Vol. 19, Iss. 3, pp. 206-221
Open Access | Times Cited: 15
Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)
Lei Zhan, Xiaojing Liu, Jing Zhang, et al.
Oncology Letters (2020) Vol. 20, Iss. 3, pp. 2075-2090
Open Access | Times Cited: 14
Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy
Wei Li, Meixiao Zhan, Yingyao Quan, et al.
International Immunopharmacology (2020) Vol. 81, pp. 106227-106227
Closed Access | Times Cited: 11
Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis
Shan-mei Chen, Chuanke Zhao, Li-cheng Yao, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 1, pp. 189-200
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top